Literature DB >> 24664092

Ceftriaxone and acute renal failure in children.

Ning Li1, Xuefeng Zhou, Jiyan Yuan, Guiying Chen, Hongliang Jiang, Wen Zhang.   

Abstract

OBJECTIVE: Our aim was to evaluate the clinical profile, treatment, and outcome of ceftriaxone-associated postrenal acute renal failure (PARF) in children.
METHODS: We retrospectively studied 31 consecutive cases from 2003 to 2012 for PARF after ceftriaxone treatment. There was no past history of urolithiasis or nephropathy in these children.
RESULTS: The average time of ceftriaxone administration before PARF was 5.2 days. The major symptoms apart from anuria included flank pain (>3 years old, 25/25), excessive crying (<3 years, 6/6), and vomiting (19/33). Ultrasound showed mild hydronephrosis (25/31) and ureteric calculi (11/31). Nine children recovered after 1 to 4 days of pharmacotherapy. Twenty-one children who were resistant to pharmacotherapy underwent retrograde ureteral catheterization. After catheterization of their ureters, normal urine flow was observed, and the symptoms subsided immediately. Catheter insertion failed in 1 child who subsequently underwent 3 sessions of hemodialysis before normal urination was restored. Ceftriaxone was verified to be the main component of the calculi in 4 children by tandem mass spectrometric analysis. The recovery was complete in all cases.
CONCLUSIONS: Ceftriaxone therapy in children may cause PARF. Early diagnosis and prompt pharmacological therapy are important in relieving the condition. Retrograde ureteral catheterization is an effective treatment of those who fail to respond to pharmacotherapy.

Entities:  

Keywords:  acute renal failure; ceftriaxone; child

Mesh:

Substances:

Year:  2014        PMID: 24664092     DOI: 10.1542/peds.2013-2103

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  5 in total

Review 1.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

Review 2.  Drug-Induced Urolithiasis in Pediatric Patients.

Authors:  Maria Chiara Sighinolfi; Ahmed Eissa; Luigi Bevilacqua; Ahmed Zoeir; Silvia Ciarlariello; Elena Morini; Stefano Puliatti; Viviana Durante; Pier Luca Ceccarelli; Salvatore Micali; Giampaolo Bianchi; Bernardo Rocco
Journal:  Paediatr Drugs       Date:  2019-10       Impact factor: 3.022

Review 3.  Characterizing ceftriaxone-induced urolithiasis and its associated acute kidney injury: an animal study and Chinese clinical systematic review.

Authors:  Yifan Zhang; Benxiang Ning; Huaijun Zhu; Xiaoming Cong; Leqing Zhou; Qiang Wang; Liming Zhang; Xizhao Sun
Journal:  Int Urol Nephrol       Date:  2016-04-28       Impact factor: 2.370

4.  Ceftriaxone-associated nephrolithiasis and gallstone in adults.

Authors:  Ghodsiyeh Azarkar; Motahare Mahi Birjand; Alireza Ehsanbakhsh; Bita Bijari; Mohammad Reza Abedini; Masood Ziaee
Journal:  Drug Healthc Patient Saf       Date:  2018-12-12

5.  Ceftriaxone Calcium Crystals Induce Acute Kidney Injury by NLRP3-Mediated Inflammation and Oxidative Stress Injury.

Authors:  Zhang Yifan; Ning Benxiang; Xu Zheng; Xu Luwei; Zhou Liuhua; Ge Yuzheng; Jia Ruipeng
Journal:  Oxid Med Cell Longev       Date:  2020-07-09       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.